

Resource Summary Report

Generated by ASWG on Aug 9, 2026

FITC anti-human CD3

RRID:AB_571907

Type: Antibody

Proper Citation

BioLegend Cat# 317306, RRID:AB_571907

Antibody Information

URL: http://antibodyregistry.org/AB_571907

Proper Citation: BioLegend Cat# 317306, RRID:AB_571907

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_571907

Vendor: BioLegend

Catalog Number: 317306

Alternative Catalog Numbers: 317305

Record Creation Time: 20250820T021750+0000

Record Last Update: 20250820T131318+0000

Ratings and Alerts

- Used for flow cytometry assay by the Human Islet Research Network community.
Contact(s): [Mark Wallet](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for FITC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Zhao Y, et al. (2026) Natural killer cell dysfunction drives keloid pathogenesis. Cell reports, 45(4), 117129.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. iScience, 29(5), 115669.

Ye H, et al. (2026) Targeting ATF4 overcomes dual resistance to chemo-immunotherapy in gastric cancer by disrupting the DNA damage response. Journal for immunotherapy of cancer, 14(6).

Yang Y, et al. (2025) The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(22), 4745.

Wu M, et al. (2025) Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. Immunity, 58(11), 2864.

Schneiderova P, et al. (2025) The SARS-CoV-2 trigger highlights host interleukin 1 genetics in Epstein-Barr virus reactivation. Cell reports, 44(7), 115859.

Xie H, et al. (2025) Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL. bioRxiv : the preprint server for biology.

Binan L, et al. (2025) Simultaneous CRISPR screening and spatial transcriptomics reveal intracellular, intercellular, and functional transcriptional circuits. Cell, 188(8), 2141.

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. Cell.

Abe Y, et al. (2025) Distinct follicular T cell subsets regulate lymphoma progression and outcomes. Cancer cell.

Raeber ME, et al. (2024) Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity, 57(9), 2232.

Zhang Y, et al. (2024) Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy. *Cell reports methods*, 4(9), 100843.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. *Cancer cell*.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Wu G, et al. (2023) Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. *Frontiers in immunology*, 14, 1093750.

Wu X, et al. (2023) Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19. *iScience*, 26(6), 106929.

Schmidt F, et al. (2023) In-depth analysis of human virus-specific CD8⁺ T cells delineates unique phenotypic signatures for T cell specificity prediction. *Cell reports*, 42(10), 113250.

Zhou Z, et al. (2022) Evaluation of the tumoricidal efficacy of adoptive cell transfer using hepatocellular carcinoma-derived organoids. *Journal of gastrointestinal oncology*, 13(2), 732.

Oyer JL, et al. (2022) Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions In Vitro and In Vivo. *Frontiers in immunology*, 13, 861681.

Gbyli R, et al. (2022) In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. *Leukemia*, 36(5), 1313.